ENCell Co., Ltd. has been selected as a final participant in the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program. The selected project is titled "Development of a Treatment for Duchenne Muscular Dystrophy Utilizing High-Potency/High-Efficiency GMP Technology for Large-Scale Expansion of Early-Passage Umbilical Cord-Derived Mesenchymal Stem Cells." ENCell Co., Ltd. will serve as the lead organization (Project Manager: CEO Jongwook Jang), with Samsung Medical Center participating as a collaborating institution (Division Manager: Professor Jihoon Lee, Department of Pediatrics).Through this project, ENCell aims to accelerate clinical trials and commercialization of its stem cell-based treatment for Duchenne Muscular Dystrophy. By securing funding support from Seoul City, the company is committed to contributing to the growth of Seoul’s bio-medical industry and pledges to dedicate itself to the development of therapies for the rare disease Duchenne Muscular Dystrophy.